|
Breast MRI
|
|
Intervention
|
Breast MRI demonstrating marked enhancement (bright area) which was confirmed to be cancer.
|
|
ICD-10-PCS
|
BH3
|
|
ICD-9-CM
|
88.92, 88.97
|
|
OPS-301 code
|
3-827
|
One alternative to mammography, Breast MRI or contrast enhanced magnetic resonance imaging (MRI), has shown substantial progress in the detection of breast cancer.
Contents
-
Comparison to other technologies 1
-
nephrogenic systemic fibrosis (NSF) 2
-
References 3
-
See also 4
Comparison to other technologies
The available literature suggests that the sensitivity of contrast-enhanced breast MRI in detection of cancer is considerably higher than that of either radiographic mammography or ultrasound and is generally reported to be in excess of 94%.[1]
The specificity (the confidence that a lesion is cancerous and not a false positive) is only fair ('modest'),[2] (or 37%-97%[1]) thus a positive finding by MRI should not be interpreted as a definitive diagnosis.
The reports of 4,271 breast MRIs from eight large scale clinical trials were reviewed in 2006.[3]
nephrogenic systemic fibrosis (NSF)
This systemic disease resembles scleromyxedema and to some extent scleroderma. It may occur months after contrast has been injected.[11] Patients with poorer renal function are more at risk for NSF, with dialysis patients being more at risk than patients with renal insufficiency.[12][13] After several years of controversy during which up to 100 Danish patients have been gadolinium poisoned (and some died) after use of the contrast agent Omniscan, it was admitted by the Norwegian medical company Nycomed that they were aware of some dangers of using gadolinium-based agents for their product.[14] At present, NSF has been linked to the use of four gadolinium-containing MRI contrast agents.[4]
References
-
^ a b Magnetic Resonance Imaging of the Breast
-
^ DeMartini W, Lehman C, Partridge S (April 2008). "Breast MRI for cancer detection and characterization: a review of evidence-based clinical applications". Acad Radiol 15 (4): 408–16.
-
^ Lehman CD (2006). "Role of MRI in screening women at high risk for breast cancer". Journal of Magnetic Resonance Imaging 24 (5): 964–70.
-
^ MRI contrast agent
See also
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.